AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18757963 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 88
Study 15956273 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (16 mg, 24 mg, or 32 mg daily)
Number of subjects: 2033
Study 15956273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2033
Study 12031821 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/day)
Number of subjects: 58
Study 12031821 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day)
Number of subjects: 58
Study 12031821 — intervention group
Group type: EXPERIMENTAL
Intervention: Both statins
Number of subjects: 58
Study 10406624 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 351
Study 10406624 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 351
Study 8602474 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpation over the facet joints in the cervical spine
Number of subjects: 75
Study 8602474 — intervention group
Group type: EXPERIMENTAL
Intervention: Test of the formina intervertebralia
Number of subjects: 75
Study 8602474 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb tension test
Number of subjects: 75
Study 8602474 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck rotation test
Number of subjects: 75
Study 8602474 — intervention group
Group type: EXPERIMENTAL
Intervention: Active flexion/extension test
Number of subjects: 75
Study 2169587 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with cisplatin (100 mg/m² on days 1 and 29) and vinblastine (5 mg/m² on days 1, 8, 15, 22, and 29) followed by radiation therapy (60 Gy over 6 weeks)
Number of subjects: 155
Study 2169587 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone (60 Gy over 6 weeks)
Number of subjects: 155
Study 2169587 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with cisplatin and vinblastine
Number of subjects: 155
Study 7315754 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG feedback
Number of subjects: 24
Study 7315754 — intervention group
Group type: EXPERIMENTAL
Intervention: Taped verbal relaxation training
Number of subjects: 24
Study 7315754 — intervention group
Group type: COMPARATOR
Intervention: No contact control
Number of subjects: 24
Study 30747964 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (acetaminophen) 1000 mg plus ibuprofen 400 mg (PCM + IBU)
Number of subjects: 556
Study 30747964 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 1000 mg (PCM)
Number of subjects: 556
Study 30747964 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg (IBU)
Number of subjects: 556
Study 30747964 — intervention group
Group type: COMPARATOR
Intervention: Half-strength paracetamol 500 mg plus ibuprofen 200 mg (HS-PCM + IBU)
Number of subjects: 556
Study 30747964 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (PCM) alone
Number of subjects: 556
Study 30747964 — intervention group
Group type: COMPARATOR
Intervention: Half-strength paracetamol plus ibuprofen (HS-PCM + IBU)
Number of subjects: 556
Study 30747964 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen alone (IBU)
Number of subjects: 556
Study 30747964 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol alone (PCM)
Number of subjects: 556
Study 30747964 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups receiving ibuprofen (IBU)
Number of subjects: 556
Study 28205056 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 5313
Study 28205056 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 5313
Study 28205056 — intervention group
Group type: COMPARATOR
Intervention: Hospitalizations
Number of subjects: 5313
Study 24753036 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting with AO stent coverage (AOC)
Number of subjects: 321
Study 24753036 — intervention group
Group type: COMPARATOR
Intervention: Stenting without AO stent coverage
Number of subjects: 321
Study 24753036 — intervention group
Group type: EXPERIMENTAL
Intervention: AOC group
Number of subjects: 321
Study 24753036 — intervention group
Group type: EXPERIMENTAL
Intervention: AOC
Number of subjects: 321
Study 23756409 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient guidance during PCI (study group)
Number of subjects: 108
Study 23756409 — intervention group
Group type: COMPARATOR
Intervention: Control group (no guidance during PCI)
Number of subjects: 108
Study 21092933 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help (GSH)
Number of subjects: 81
Study 21092933 — intervention group
Group type: COMPARATOR
Intervention: Waiting list condition (Control)
Number of subjects: 81
Study 19999017 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol and ipratropium bromide administered by device of measured doses and space chamber
Number of subjects: 45
Study 19999017 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol and ipratropium bromide nebulized with supplementary oxygen
Number of subjects: 45
Study 17339868 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5 functional allele carriers
Number of subjects: 1398
Study 17339868 — intervention group
Group type: COMPARATOR
Intervention: CYP3A5 non-functional allele carriers
Number of subjects: 1398
Study 17339868 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5 functional allele carriers (blacks)
Number of subjects: 1398
Study 17339868 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5 functional allele carriers (Hispanics)
Number of subjects: 1398
Study 17339868 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5 functional allele carriers (whites)
Number of subjects: 1398
Study 17339868 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5 genotype
Number of subjects: 1398
Study 14981346 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg once daily + ASA 75 mg once daily
Number of subjects: 7599
Study 14981346 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg once daily
Number of subjects: 7599
Study 11685162 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and ticlopidine
Number of subjects: 196
Study 11685162 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 196
Study 9511113 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg twice daily for 2 to 3 weeks)
Number of subjects: 83
Study 9511113 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime axetil (250 mg twice daily for 2 to 3 weeks)
Number of subjects: 83
Study 9511113 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 83
Study 9511113 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime axetil
Number of subjects: 83
Study 7974935 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/day propiverine
Number of subjects: 66
Study 7974935 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day propiverine
Number of subjects: 66
Study 7974935 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mg/day propiverine
Number of subjects: 66
Study 7974935 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/day propiverine
Number of subjects: 66
Study 7974935 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiverine (doses of 15, 30, 45 and 60 mg/day)
Number of subjects: 66
Study 2647494 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin plus dipyridamole
Number of subjects: 209
Study 2647494 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal plus dipyridamole
Number of subjects: 209
Study 2647494 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus dipyridamole
Number of subjects: 209
Study 4908342 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-adamantanamine hydrochloride (aminoadamantane) 100 mg every 12 hours for 10 days
Number of subjects: 0
Study 4908342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31200641 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed intermittent bolus (PIB)
Number of subjects: 42
Study 31200641 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural infusion (CEI)
Number of subjects: 42
Study 28477414 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin therapy
Number of subjects: 625
Study 28477414 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin therapy
Number of subjects: 625
Study 28477414 — intervention group
Group type: EXPERIMENTAL
Intervention: Prandial insulin therapy
Number of subjects: 625
Study 28477414 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycated albumin
Number of subjects: 625
Study 28477414 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 625
Study 25200448 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music for 10 min
Number of subjects: 92
Study 25200448 — intervention group
Group type: COMPARATOR
Intervention: Waiting in silence
Number of subjects: 92
Study 23648946 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan, 10 mg/d
Number of subjects: 492
Study 23648946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 492
Study 21314920 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 204
Study 21314920 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 204
Study 21314920 — intervention group
Group type: COMPARATOR
Intervention: Talking Control (TC)
Number of subjects: 204
Study 19826286 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load resistance training with slow movement and tonic force generation (LST) at approximately 60% 1RM, 3-second lifting, and 3-second lowering, performed twice a week for 13 weeks
Number of subjects: 24
Study 19826286 — intervention group
Group type: COMPARATOR
Intervention: High-intensity exercise at normal speed (HM) at 85% 1RM, 1-second lifting, 1-second lowering, and 1-second relaxed movement, performed twice a week for 13 weeks
Number of subjects: 24
Study 19826286 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control (CON) group
Number of subjects: 24
Study 16566418 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0
Study 16566418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15356664 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-centered monitoring through telemedicine (measuring blood pressure and body weight three times a week for 6 months)
Number of subjects: 122
Study 15356664 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-centered monitoring through telemedicine
Number of subjects: 122
Study 15356664 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital care
Number of subjects: 122
Study 11579330 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg of morphine following induction and placebo saline during peritoneal closure
Number of subjects: 60
Study 11579330 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo saline following induction and 0.15 mg/kg of morphine during peritoneal closure
Number of subjects: 60
Study 11579330 — intervention group
Group type: COMPARATOR
Intervention: Placebo saline both during induction and peritoneal closure
Number of subjects: 60
Study 9685791 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional trabeculectomy
Number of subjects: 141
Study 9685791 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification with sutures
Number of subjects: 141
Study 9685791 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacotrabeculectomy
Number of subjects: 141
Study 9685791 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutureless phacoemulsification
Number of subjects: 141
Study 9685791 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 141
Study 8304366 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 315
Study 8304366 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 315
Study 8304366 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 315
Study 8304366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study 3289113 — intervention group
Group type: EXPERIMENTAL
Intervention: Olsalazine
Number of subjects: 8
Study 3289113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29599067 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Bypass (PB)
Number of subjects: 239
Study 28822510 — intervention group
Group type: EXPERIMENTAL
Intervention: 80-mg atorvastatin
Number of subjects: 1027
Study 28822510 — intervention group
Group type: COMPARATOR
Intervention: 10-mg atorvastatin
Number of subjects: 1027
Study 26296862 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol administered via dry powder inhalers
Number of subjects: 60
Study 22680300 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 1: 90% anorganic bovine bone + 10% porcine collagen fibers + resorbable bilayer membrane (non-cross-linked porcine types I and III collagen)
Number of subjects: 44
Study 22680300 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 2: 70% cross-linked type I bovine collagen sponge + non-sintered hydroxyapatite + resorbable membrane (type I porcine collagen cross-linked by natural ribose glycation)
Number of subjects: 44
Study 22680300 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both protocols
Number of subjects: 44
Study 21604899 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term treatment for GAD patients
Number of subjects: 52
Study 21604899 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term treatment for GAD patients (Overly Nurturant subtype)
Number of subjects: 52
Study 21604899 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term treatment for GAD patients (Intrusive subtype)
Number of subjects: 52
Study 21604899 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term treatment for GAD patients (Socially Avoidant subtype)
Number of subjects: 52
Study 21604899 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term treatment for GAD patients (Nonassertive subtype)
Number of subjects: 52
Study 18426626 — intervention group
Group type: EXPERIMENTAL
Intervention: FM-TCI
Number of subjects: 56
Study 18426626 — intervention group
Group type: COMPARATOR
Intervention: MCI-controlled
Number of subjects: 56
Study 12625833 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogen (CEE; 0.625 mg/day; n = 14)
Number of subjects: 40
Study 12625833 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (150 mg/day; n = 13)
Number of subjects: 40
Study 12625833 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 13)
Number of subjects: 40
Study 10658376 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-bonded circuit
Number of subjects: 24
Study 10658376 — intervention group
Group type: COMPARATOR
Intervention: Nonheparin-bonded control circuit
Number of subjects: 24
Study 8557867 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 g nitrogen (N)/kg Ideal Body Weight (IBW)
Number of subjects: 35
Study 8557867 — intervention group
Group type: COMPARATOR
Intervention: 0.12 g nitrogen (N)/kg Ideal Body Weight (IBW)
Number of subjects: 35
Study 8557867 — intervention group
Group type: COMPARATOR
Intervention: 0.18 g nitrogen (N)/kg Ideal Body Weight (IBW)
Number of subjects: 35
Study 2128866 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg
Number of subjects: 55
Study 2128866 — intervention group
Group type: COMPARATOR
Intervention: Colestyramine 16 g
Number of subjects: 55
Study 488523 — intervention group
Group type: EXPERIMENTAL
Intervention: sulphinpyrazone (600‐800 mg daily)
Number of subjects: 41
Study 488523 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 41
Study 30680870 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent programme (n = 30)
Number of subjects: 60
Study 30680870 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (n = 30)
Number of subjects: 60
Study 28161147 — intervention group
Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation (PRP)
Number of subjects: 305
Study 28161147 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg/0.05 ml)
Number of subjects: 305
Study 28161147 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern scan PRP
Number of subjects: 305
Study 28161147 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional single-spot PRP
Number of subjects: 305
Study 28161147 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk PDR or worse
Number of subjects: 305
Study 28161147 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate PDR or better
Number of subjects: 305
Study 25860005 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicyclol 75 mg/day (25 mg three times daily) in conjunction with glucurolactone 600 mg/day (200 mg three times daily)
Number of subjects: 240
Study 25860005 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving glucurolactone 600 mg/day (200 mg three times daily) only
Number of subjects: 240
Study 25860005 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 240
Study 23712523 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling kit for HPV testing
Number of subjects: 0
Study 23712523 — intervention group
Group type: COMPARATOR
Intervention: Second invitation for a free Pap-smear
Number of subjects: 0
Study 22313831 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic block grafts impregnated with autologous bone marrow
Number of subjects: 10
Study 22313831 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic block grafts (control group)
Number of subjects: 10
Study 19576349 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary angioplasty with stent implantation
Number of subjects: 1572
Study 19576349 — intervention group
Group type: COMPARATOR
Intervention: In-hospital fibrinolysis with alteplase
Number of subjects: 1572
Study 17241493 — intervention group
Group type: EXPERIMENTAL
Intervention: Relational Psychotherapy Mothers' Group (RPMG)
Number of subjects: 127
Study 17241493 — intervention group
Group type: COMPARATOR
Intervention: Recovery Training (RT)
Number of subjects: 127
Study 15789978 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate 360 degrees toothbrush
Number of subjects: 31
Study 15789978 — intervention group
Group type: COMPARATOR
Intervention: Oral‐B Indicator toothbrush
Number of subjects: 31
Study 15789978 — intervention group
Group type: COMPARATOR
Intervention: Crest SpinBrush PRO toothbrush
Number of subjects: 31
Study 15789978 — intervention group
Group type: COMPARATOR
Intervention: Oral‐B CrossAction toothbrush
Number of subjects: 31
Study 11748775 — intervention group
Group type: EXPERIMENTAL
Intervention: haloperidol (0.5 to 2 mg/day)
Number of subjects: 58
Study 11748775 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone (0.5 to 2 mg/day)
Number of subjects: 58
Study 9597563 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release morphine suppositories (MSC-R)
Number of subjects: 27
Study 9597563 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release morphine tablets (MSC-T)
Number of subjects: 27
Study 8044919 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive lipoprotein manipulation
Number of subjects: 2095
Study 29705451 — intervention group
Group type: EXPERIMENTAL
Intervention: Barberry juice (BJ), 200 ml daily for 8 weeks
Number of subjects: 46
Study 29705451 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 46
Study 28006831 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin melt (lyophilisate)
Number of subjects: 134
Study 28006831 — intervention group
Group type: COMPARATOR
Intervention: Desmopressin tablets
Number of subjects: 134
Study 28006831 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (melt and tablets)
Number of subjects: 134
Study 26037429 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-fortified salt (DFS) containing 47 mg of potassium iodate and 3300 mg of microencapsulated ferrous fumarate (1100 mg elemental iron) per kg of salt
Number of subjects: 245
Study 26037429 — intervention group
Group type: COMPARATOR
Intervention: Iodized salt (control group)
Number of subjects: 245
Study 26037429 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-fortified salt (DFS)
Number of subjects: 245
Study 22540849 — intervention group
Group type: EXPERIMENTAL
Intervention: Equipercentile equating method
Number of subjects: 2200
Study 22540849 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear equating method
Number of subjects: 2200
Study 22540849 — intervention group
Group type: COMPARATOR
Intervention: Raw AVLT scores
Number of subjects: 2200
Study 20163984 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic slow eye movement (SEM) analysis during the multiple sleep latency test (MSLT)
Number of subjects: 20
Study 20163984 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic slow eye movement (SEM) analysis during the maintenance of wakefulness test (MWT)
Number of subjects: 20
Study 20163984 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of SEM latency with sleep latency at MSLT
Number of subjects: 20
Study 20163984 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of SEM latency with sleep latency at MWT
Number of subjects: 20
Study 20163984 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of Epworth Sleepiness Scale score with SEM latency at MWT
Number of subjects: 20
Study 20163984 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of Epworth Sleepiness Scale score with SEM latency at MSLT
Number of subjects: 20
Study 19635340 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises and urge suppression techniques
Number of subjects: 0
Study 16788299 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular dose ASA+MR-DP (b.i.d. on days 5-28)
Number of subjects: 146
Study 16788299 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced dose ASA+MR-DP (once daily before bed during days 5-14, b.i.d. on days 15-28)
Number of subjects: 146
Study 16788299 — intervention group
Group type: COMPARATOR
Intervention: Placebo (days 1-28)
Number of subjects: 146
Study 15299060 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ) administered intravenously at a dosage of 1 g
Number of subjects: 10
Study 15299060 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-infusion H(2)(15)O PET
Number of subjects: 10